These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 25306392)

  • 1. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma.
    Pricl S; Cortelazzi B; Dal Col V; Marson D; Laurini E; Fermeglia M; Licitra L; Pilotti S; Bossi P; Perrone F
    Mol Oncol; 2015 Feb; 9(2):389-97. PubMed ID: 25306392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular basis of drug resistance in smoothened receptor: An in silico study of protein resistivity and specificity.
    Sinha N; Chowdhury S; Sarkar RR
    Proteins; 2020 Mar; 88(3):514-526. PubMed ID: 31589795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.
    Yauch RL; Dijkgraaf GJ; Alicke B; Januario T; Ahn CP; Holcomb T; Pujara K; Stinson J; Callahan CA; Tang T; Bazan JF; Kan Z; Seshagiri S; Hann CL; Gould SE; Low JA; Rudin CM; de Sauvage FJ
    Science; 2009 Oct; 326(5952):572-4. PubMed ID: 19726788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.
    Sharpe HJ; Pau G; Dijkgraaf GJ; Basset-Seguin N; Modrusan Z; Januario T; Tsui V; Durham AB; Dlugosz AA; Haverty PM; Bourgon R; Tang JY; Sarin KY; Dirix L; Fisher DC; Rudin CM; Sofen H; Migden MR; Yauch RL; de Sauvage FJ
    Cancer Cell; 2015 Mar; 27(3):327-41. PubMed ID: 25759019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical characterization of smoothened receptor antagonists by binding kinetics against drug-resistant mutant.
    Shimizu Y; Ishii T; Ogawa K; Sasaki S; Matsui H; Nakayama M
    Eur J Pharmacol; 2015 Oct; 764():220-227. PubMed ID: 26048307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy.
    Buetti-Dinh A; Jensen R; Friedman R
    BMC Cancer; 2018 May; 18(1):569. PubMed ID: 29776351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor.
    Skvara H; Kalthoff F; Meingassner JG; Wolff-Winiski B; Aschauer H; Kelleher JF; Wu X; Pan S; Mickel L; Schuster C; Stary G; Jalili A; David OJ; Emotte C; Antunes AM; Rose K; Decker J; Carlson I; Gardner H; Stuetz A; Bertolino AP; Stingl G; De Rie MA
    J Invest Dermatol; 2011 Aug; 131(8):1735-44. PubMed ID: 21430703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy.
    Sánchez-Danés A; Larsimont JC; Liagre M; Muñoz-Couselo E; Lapouge G; Brisebarre A; Dubois C; Suppa M; Sukumaran V; Del Marmol V; Tabernero J; Blanpain C
    Nature; 2018 Oct; 562(7727):434-438. PubMed ID: 30297799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists.
    Metcalfe C; de Sauvage FJ
    Cancer Res; 2011 Aug; 71(15):5057-61. PubMed ID: 21771911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas.
    Piérard-Franchimont C; Hermanns-Lê T; Paquet P; Herfs M; Delvenne P; Piérard GE
    Future Oncol; 2015 Nov; 11(22):2997-3002. PubMed ID: 26437034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vismodegib resistance in basal cell carcinoma: not a smooth fit.
    Ridky TW; Cotsarelis G
    Cancer Cell; 2015 Mar; 27(3):315-6. PubMed ID: 25759014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against Vismodegib-resistant Smoothened mutant.
    Ishii T; Shimizu Y; Nakashima K; Kondo S; Ogawa K; Sasaki S; Matsui H
    Eur J Pharmacol; 2014 Jan; 723():305-13. PubMed ID: 24291104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Smoothened variants explain the majority of drug resistance in basal cell carcinoma.
    Atwood SX; Sarin KY; Whitson RJ; Li JR; Kim G; Rezaee M; Ally MS; Kim J; Yao C; Chang AL; Oro AE; Tang JY
    Cancer Cell; 2015 Mar; 27(3):342-53. PubMed ID: 25759020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.
    Danial C; Sarin KY; Oro AE; Chang AL
    Clin Cancer Res; 2016 Mar; 22(6):1325-9. PubMed ID: 26546616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and preclinical development of vismodegib.
    Gould SE; Low JA; Marsters JC; Robarge K; Rubin LL; de Sauvage FJ; Sutherlin DP; Wong H; Yauch RL
    Expert Opin Drug Discov; 2014 Aug; 9(8):969-84. PubMed ID: 24857041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in the hedgehog pathway genes SMO and PTCH1 in human gastric tumors.
    Wang XD; Inzunza H; Chang H; Qi Z; Hu B; Malone D; Cogswell J
    PLoS One; 2013; 8(1):e54415. PubMed ID: 23349881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations.
    Galimberti F; Busch AM; Chinyengetere F; Ma T; Sekula D; Memoli VA; Dragnev KH; Liu F; Johnson KC; Guo Y; Freemantle SJ; Andrew AS; Greninger P; Robbins DJ; Settleman J; Benes C; Dmitrovsky E
    Int J Oncol; 2012 Nov; 41(5):1751-61. PubMed ID: 22923130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Not Available].
    Basset-Seguin N
    Ann Dermatol Venereol; 2018 Nov; 145 Suppl 5():VS36-VS41. PubMed ID: 30477683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.
    Danhof R; Lewis K; Brown M
    Am J Clin Dermatol; 2018 Apr; 19(2):195-207. PubMed ID: 28887802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of vismodegib resistance in D473G and W535L mutants of SMO receptor and design of novel drug derivatives using molecular dynamics simulations.
    Liao S; Floyd C; Verratti N; Leung L; Wu C
    Life Sci; 2020 Mar; 244():117302. PubMed ID: 31953165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.